210 related articles for article (PubMed ID: 37545530)
1. Lenvatinib improves anti-PD-1 therapeutic efficacy by promoting vascular normalization via the NRP-1-PDGFRβ complex in hepatocellular carcinoma.
Yang J; Guo Z; Song M; Pan Q; Zhao J; Huang Y; Han Y; Ouyang D; Yang C; Chen H; Di M; Tang Y; Zhu Q; Wang Q; Li Y; He J; Weng D; Xiang T; Xia J
Front Immunol; 2023; 14():1212577. PubMed ID: 37545530
[TBL] [Abstract][Full Text] [Related]
2. Dual Vascular Endothelial Growth Factor Receptor and Fibroblast Growth Factor Receptor Inhibition Elicits Antitumor Immunity and Enhances Programmed Cell Death-1 Checkpoint Blockade in Hepatocellular Carcinoma.
Deng H; Kan A; Lyu N; Mu L; Han Y; Liu L; Zhang Y; Duan Y; Liao S; Li S; Xie Q; Gao T; Li Y; Zhang Z; Zhao M
Liver Cancer; 2020 Jun; 9(3):338-357. PubMed ID: 32647635
[TBL] [Abstract][Full Text] [Related]
3. Immunomodulatory activity of lenvatinib contributes to antitumor activity in the Hepa1-6 hepatocellular carcinoma model.
Kimura T; Kato Y; Ozawa Y; Kodama K; Ito J; Ichikawa K; Yamada K; Hori Y; Tabata K; Takase K; Matsui J; Funahashi Y; Nomoto K
Cancer Sci; 2018 Dec; 109(12):3993-4002. PubMed ID: 30447042
[TBL] [Abstract][Full Text] [Related]
4. Lenvatinib Plus Anti-PD-1 Combination Therapy for Advanced Cancers: Defining Mechanisms of Resistance in an Inducible Transgenic Model of Thyroid Cancer.
Bertol BC; Bales ES; Calhoun JD; Mayberry A; Ledezma ML; Sams SB; Orlicky DJ; Donadi EA; Haugen BR; French JD
Thyroid; 2022 Feb; 32(2):153-163. PubMed ID: 34641722
[No Abstract] [Full Text] [Related]
5. Inhibition of FGFR Reactivates IFNγ Signaling in Tumor Cells to Enhance the Combined Antitumor Activity of Lenvatinib with Anti-PD-1 Antibodies.
Adachi Y; Kamiyama H; Ichikawa K; Fukushima S; Ozawa Y; Yamaguchi S; Goda S; Kimura T; Kodama K; Matsuki M; Miyano SW; Yokoi A; Kato Y; Funahashi Y
Cancer Res; 2022 Jan; 82(2):292-306. PubMed ID: 34753772
[TBL] [Abstract][Full Text] [Related]
6. Lenvatinib Targets FGF Receptor 4 to Enhance Antitumor Immune Response of Anti-Programmed Cell Death-1 in HCC.
Yi C; Chen L; Lin Z; Liu L; Shao W; Zhang R; Lin J; Zhang J; Zhu W; Jia H; Qin L; Lu L; Chen J
Hepatology; 2021 Nov; 74(5):2544-2560. PubMed ID: 34036623
[TBL] [Abstract][Full Text] [Related]
7. Tumor-derived lactate inhibit the efficacy of lenvatinib through regulating PD-L1 expression on neutrophil in hepatocellular carcinoma.
Deng H; Kan A; Lyu N; He M; Huang X; Qiao S; Li S; Lu W; Xie Q; Chen H; Lai J; Chen Q; Jiang X; Liu S; Zhang Z; Zhao M
J Immunother Cancer; 2021 Jun; 9(6):. PubMed ID: 34168004
[TBL] [Abstract][Full Text] [Related]
8. Antitumor and Antiangiogenic Activities of Lenvatinib in Mouse Xenograft Models of Vascular Endothelial Growth Factor-Induced Hypervascular Human Hepatocellular Carcinoma.
Adachi Y; Matsuki M; Watanabe H; Takase K; Kodama K; Matsui J; Funahashi Y; Nomoto K
Cancer Invest; 2019; 37(4-5):185-198. PubMed ID: 31006280
[TBL] [Abstract][Full Text] [Related]
9. Lenvatinib Might Induce Activation of Host Immunity in Patients with Hepatocellular Carcinoma.
Nagai H; Mukozu T; Kobayashi K; Nogami A; Nagumo H; Mohri K; Watanabe G; Amanuma M; Yoshimine N; Ogino Y; Matsui D; Daido Y; Matsukiyo Y; Matsui T; Wakui N; Momiyama K; Higai K; Matsuda T
Oncology; 2023; 101(1):32-40. PubMed ID: 36191570
[TBL] [Abstract][Full Text] [Related]
10. Tanshinone IIA normalized hepatocellular carcinoma vessels and enhanced PD-1 inhibitor efficacy by inhibiting ELTD1.
Mao D; Wang H; Guo H; Che X; Chen M; Li X; Liu Y; Huo J; Chen Y
Phytomedicine; 2024 Jan; 123():155191. PubMed ID: 38000104
[TBL] [Abstract][Full Text] [Related]
11. Correlation and efficacy of TACE combined with lenvatinib plus PD-1 inhibitor in the treatment of hepatocellular carcinoma with portal vein tumor thrombus based on immunological features.
Zou X; Xu Q; You R; Yin G
Cancer Med; 2023 May; 12(10):11315-11333. PubMed ID: 36951443
[TBL] [Abstract][Full Text] [Related]
12. Metformin synergistically enhances the antitumour activity of Lenvatinib in hepatocellular carcinoma by altering AKT-FOXO3 signalling pathway.
Cheng Y; Zhan P; Lu J; Lu Y; Luo C; Cen X; Wang F; Xie C; Yin Z
Liver Int; 2023 Jul; 43(7):1577-1592. PubMed ID: 37208925
[TBL] [Abstract][Full Text] [Related]
13. Sophoridine suppresses lenvatinib-resistant hepatocellular carcinoma growth by inhibiting RAS/MEK/ERK axis via decreasing VEGFR2 expression.
Zhao Z; Zhang D; Wu F; Tu J; Song J; Xu M; Ji J
J Cell Mol Med; 2021 Jan; 25(1):549-560. PubMed ID: 33210432
[TBL] [Abstract][Full Text] [Related]
14. Acquisition of mesenchymal-like phenotypes and overproduction of angiogenic factors in lenvatinib-resistant hepatocellular carcinoma cells.
Ao J; Chiba T; Shibata S; Kurosugi A; Qiang N; Ma Y; Kan M; Iwanaga T; Sakuma T; Kanzaki H; Kanayama K; Kojima R; Kusakabe Y; Nakamura M; Saito T; Nakagawa R; Kondo T; Ogasawara S; Suzuki E; Muroyama R; Kato J; Mimura N; Kanda T; Maruyama H; Kato N
Biochem Biophys Res Commun; 2021 Apr; 549():171-178. PubMed ID: 33676186
[TBL] [Abstract][Full Text] [Related]
15. Lenvatinib combined with nivolumab in advanced hepatocellular carcinoma-real-world experience.
Wu WC; Lin TY; Chen MH; Hung YP; Liu CA; Lee RC; Huang YH; Chao Y; Chen SC
Invest New Drugs; 2022 Aug; 40(4):789-797. PubMed ID: 35477812
[TBL] [Abstract][Full Text] [Related]
16. Real-world efficiency of lenvatinib plus PD-1 blockades in advanced hepatocellular carcinoma: an exploration for expanded indications.
Sun X; Zhang Q; Mei J; Yang Z; Chen M; Liang T
BMC Cancer; 2022 Mar; 22(1):293. PubMed ID: 35305593
[TBL] [Abstract][Full Text] [Related]
17. siRNA targeting PD-L1 delivered with attenuated Salmonella enhanced the anti-tumor effect of lenvatinib on mice bearing Hepatocellular carcinoma.
Chen P; Li Y; Wei P; Liang L; Li B; Cao Y; Han X; Wang Y; Duan X; Jia H; Zhao T; Ren J
Int Immunopharmacol; 2022 Oct; 111():109127. PubMed ID: 35964407
[TBL] [Abstract][Full Text] [Related]
18. Antiproliferative Effect of Lenvatinib on Human Liver Cancer Cell Lines
Ogasawara S; Mihara Y; Kondo R; Kusano H; Akiba J; Yano H
Anticancer Res; 2019 Nov; 39(11):5973-5982. PubMed ID: 31704822
[TBL] [Abstract][Full Text] [Related]
19. Phase 2 study of lenvatinib in patients with advanced hepatocellular carcinoma.
Ikeda K; Kudo M; Kawazoe S; Osaki Y; Ikeda M; Okusaka T; Tamai T; Suzuki T; Hisai T; Hayato S; Okita K; Kumada H
J Gastroenterol; 2017 Apr; 52(4):512-519. PubMed ID: 27704266
[TBL] [Abstract][Full Text] [Related]
20. Effects of liver-targeted drugs on expression of immune-related proteins in hepatocellular carcinoma cells.
Qiu MJ; He XX; Bi NR; Wang MM; Xiong ZF; Yang SL
Clin Chim Acta; 2018 Oct; 485():103-105. PubMed ID: 29940148
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
